To access the full text documents, please follow this link: http://hdl.handle.net/2445/120231
dc.contributor.author | Fernández de Misa, Ricardo |
---|---|
dc.contributor.author | Hernández Machín, B. |
dc.contributor.author | Servitje Bedate, Octavio |
dc.contributor.author | Valentí Medina, Francesc |
dc.contributor.author | Maroñas Jiménez, L. |
dc.contributor.author | Ortiz Romero, Pablo L. |
dc.contributor.author | Sánchez Schmidt, Júlia |
dc.contributor.author | Pujol, Ramon M. |
dc.contributor.author | Gallardo, Fernando |
dc.contributor.author | Pau Charles, I. |
dc.contributor.author | Garcia-Muret, Maria P. |
dc.contributor.author | Pérez Gala, S. |
dc.contributor.author | Román, Concepción |
dc.contributor.author | Cañueto, J. |
dc.contributor.author | Blanch Rius, L. |
dc.contributor.author | Izu, Rosa |
dc.contributor.author | Ortiz Brugués, Ariadna |
dc.contributor.author | Martí, Rosa M. |
dc.contributor.author | Blanes, M. |
dc.contributor.author | Morillo, Mercedes |
dc.contributor.author | Sánchez, P. |
dc.contributor.author | Peñate, Yerai |
dc.contributor.author | Bastida, J. |
dc.contributor.author | Pérez Gil, Amalia |
dc.contributor.author | Lopez Lerma, Ingrid |
dc.contributor.author | Muniesa Montserrat, Cristina |
dc.contributor.author | Estrach Panella, Ma. Teresa (María Teresa) |
dc.date | 2018-02-26T09:33:56Z |
dc.date | 2018-10-10T05:10:20Z |
dc.date | 2018-03 |
dc.date | 2018-02-26T09:33:56Z |
dc.identifier | 0307-6938 |
dc.identifier | 674076 |
dc.identifier | 28994134 |
dc.identifier.uri | http://hdl.handle.net/2445/120231 |
dc.description | Background: Data regarding response to treatment in lymphomatoid papulosis (LyP) are scarce. Aim: To assess the daily clinical practice approach to LyP and the response to first-line treatments. Methods: This was a retrospective study enrolling 252 patients with LyP. Results: Topical steroids, methotrexate and phototherapy were the most common first-line treatments, prescribed for 35%, 20% and 14% of the patients, respectively. Complete response (CR) was achieved in 48% of treated patients. Eczematous lesions significantly increased relative risk (RR) of not achieving CR (RR = 1.76; 95% CI 1.16-2.11). Overall median time to CR was 10 months (95% CI 6-13 months), and 78% of complete responders showed cutaneous relapse; both results were similar for all treatment groups (P > 0.05). Overall estimated median disease-free survival (DFS) was 11 months (95% CI 9-13 months) but DFS for patients treated with phototherapy was 23 months (95% CI 10-36 months; P < 0.03). Having the Type A LyP variant (RR = 2.04; 95% CI 0.96-4.30) and receiving a first-line treatment other than phototherapy (RR = 5.33; 95% CI 0.84-33.89) were significantly associated with cutaneous early relapse. Of the 252 patients, 31 (13%) had associated mycosis fungoides unrelated to therapeutic approach, type of LyP or T-cell receptor clonality. Conclusions: Current epidemiological, clinical and pathological data support previous results. Topical steroids, phototherapy and methotrexate are the most frequently prescribed first-line treatments. Although CR and cutaneous relapse rates do not differ between them, phototherapy achieves a longer DFS. Presence of Type A LyP and use of topical steroid or methotrexate were associated with an increased risk of early relapse. |
dc.format | 7 p. |
dc.format | application/pdf |
dc.language | eng |
dc.publisher | Wiley |
dc.relation | Versió postprint del document publicat a: https://doi.org/10.1111/ced.13256. |
dc.relation | Clinical and Experimental Dermatology, 2018, vol. 43, num. 2, p. 137-143 |
dc.relation | https://doi.org/10.1111/ced.13256 |
dc.rights | (c) British Association of Dermatologists, 2017 |
dc.rights | info:eu-repo/semantics/openAccess |
dc.subject | Limfomes |
dc.subject | Malalties de la pell |
dc.subject | Fototeràpia |
dc.subject | Lymphomas |
dc.subject | Skin diseases |
dc.subject | Phototherapy |
dc.title | First-line treatment in lymphomatoid papulosis: a retrospective multicentre study |
dc.type | info:eu-repo/semantics/article |
dc.type | info:eu-repo/semantics/acceptedVersion |